Radiopharm And Lantheus Sign A Collaborative Agreement Focusing On Oncology Advancements

Radiopharm Theranostics is a biopharmaceutical company specialising in oncology radiopharmaceuticals. The firm has announced a strategic co-development partnership with Lantheus. The partnership will focus on advancing innovative cancer treatments in Australia. This collaboration also highlights their shared mission to address patients' unmet medical needs in oncology therapies.

Lantheus CEO Brian Markison said in a statement, “This partnership is an important step forward in our purpose to advance our best-in-class radiopharmaceutical therapies. Radiopharm’s deep expertise and capabilities in Australia make them an ideal collaborator for this endeavour.”

Under the terms of the agreement, Radiopharm will be involved in clinical development in Australia through its clinical development capabilities and facilities. The partnership includes plans for a basket trial targeting various solid tumours; this signifies the companies' dedication to improving cancer care.

Riccardo Canevari, CEO of Radiopharm, mentioned, “We are thrilled to collaborate with Lantheus, a global leader in radiopharmaceuticals. This partnership strengthens our ability to bring innovative treatments to needy patients and demonstrates the power of combining our expertise and resources.”

Lantheus will fully fund the clinical development program. Radiopharm is set to receive milestone payments of up to 2 million USD upon reaching critical development goals, including ethics approval, initial patient dosing, and the completion of patient enrollment for the first imaging trial under this partnership.